CERo Therapeutics receives Nasdaq delisting notice for equity shortfall, appeals

CERO THERAPEUTICS HOLDINGS, INC.

Nasdaq staff determined company fails minimum $2.5M stockholders' equity requirement for continued listing.
Trading suspension and delisting scheduled for September 8, 2025, unless hearing stays action.
Company requested hearing on September 3, 2025, to appeal determination and present compliance plan.
Plan may include public or private financing to increase equity; no assurance of success.
Company subject to mandatory hearings panel monitor until May 7, 2026, after prior non-compliance.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.